Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$85.05 USD
+1.09 (1.30%)
Updated May 31, 2024 04:00 PM ET
After-Market: $85.19 +0.14 (0.16%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth B Momentum F VGM
Brokerage Reports
Ligand Pharmaceuticals Incorporated [LGND]
Reports for Purchase
Showing records 201 - 220 ( 717 total )
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
We Think CE-Iohexol Driving Fast Toward Next Partnered Asset; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
3Q19 Results; Multiple Assets Set to Deliver Key Data and Continue to Validate Business Strategy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Captisol Continues to Bring Value With Ganaxolone Succeeding in Phase 2; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Visions of Growing Kyprolis Royalties Dancing in Our Heads; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Continuing Deal Flow and Strong Fundamentals Continue to Place Spotlight on Major Valuation Disconnect
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Kyprolis Blocking and Tackling Continues; Views on Captisol Franchise; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
2Q19 Results; Pipeline and Partnerships Keep Expanding; Valuation Remains Compelling
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Adding More Attractive Bells and Whistles to OmniAb Platform; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
First Nice View Into CE-Iohexol Phase 1 Study; No Surprises Here; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Always the Busy Bees; Nice Captisol and VDP Moves; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J